About: Molecular detection of respiratory viruses in immunocopromised ICU patients: Incidence and meaning

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Molecular detection of respiratory viruses in immunocopromised ICU patients: Incidence and meaning Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Molecular detection of respiratory viruses in immunocopromised ICU patients: Incidence and meaning
Creator	Simon, François Darmon, Michael Azoulay, Élie Canet, Emmanuel Legoff, Jérôme Lemiale, Virginie Mariotte, Eric Schlemmer, Benoît Schnell, David Seguin, Amélie
Source	Elsevier; Medline; PMC
abstract	Summary Purpose Prospective single-center study to assess the sensitivity and clinical relevance of molecular testing for respiratory viruses in critically ill immunocompromised patients with acute respiratory failure (ARF). Methods 100 consecutive critically ill immunocompromised patients with ARF in 2007–2009. Among them, 65 had hematologic malignancies (including 14 hematopoietic stem cell transplant recipients), 22 had iatrogenic immunosuppression, and 13 had solid malignancies. A multiplex molecular assay (MMA) was added to the usual battery of tests performed to look for causes of ARF. Results Nasopharyngeal aspirates and/or bronchoalveolar lavage fluid were tested for respiratory viruses using both the MMA and immunofluorescence. A virus was detected in 47 (47%) patients using the MMA and 8 (8%) patients using immunofluorescence (P = 0.006). MMA-positive and MMA-negative patients had similar clinical and radiographic presentations and were not significantly different for the use of ventilatory support (58% vs. 76%, P = 0.09), occurrence of shock (43% vs. 53%, P = 0.41), use of renal replacement therapy (26% vs. 23%, P = 0.92), SAPS II (35 [26–44] vs. 38 [27–50], P = 0.36), time spent in the ICU (6 vs. 7 days, P = 0.35), or ICU mortality (17% vs. 28%, P = 0.27). Using MMA, a virus was found in 6 of the 12 patients with no diagnosis at the end of the etiologic investigations. Conclusions In critically ill immunocompromised patients, an MMA was far more sensitive than immunofluorescence for respiratory virus detection. Patients with RVs detected in the respiratory tract had the same clinical characteristics and outcomes as other patients.
has issue date	2012-08-31(xsd:dateTime)
bibo:doi	10.1016/j.rmed.2012.05.001
bibo:pmid	22647492
has license	els-covid
sha1sum (hex)	4d2e83e8e3bc27a0f3fd437ba8ad049aaeee3d99
schema:url	https://doi.org/10.1016/j.rmed.2012.05.001
resource representing a document's title	Molecular detection of respiratory viruses in immunocopromised ICU patients: Incidence and meaning
has PubMed Central identifier	PMC7126300
has PubMed identifier	22647492
schema:publication	Respiratory Medicine
resource representing a document's body	covid:4d2e83e8e3bc27a0f3fd437ba8ad049aaeee3d99#body_text
is schema:about of	named entity 'PATIENTS' named entity 'RESPIRATORY VIRUSES' named entity 'ARF' named entity 'investigations' named entity 'virus' named entity 'immunocompromised' named entity 'assess' named entity 'respiratory' named entity 'MOLECULAR' named entity '100' named entity 'STUDY' named entity 'CAUSES' named entity 'HEMATOLOGIC MALIGNANCIES' named entity 'MOLECULAR ASSAY' named entity 'METHODS' named entity 'DIFFERENT' named entity 'ICU' named entity 'VIRUS' named entity 'SAPS' named entity 'POLYMERASE CHAIN REACTION ASSAY' named entity 'VENTILATORY SUPPORT' named entity 'RESPIRATORY MEDICINE' named entity 'RESULTS' named entity 'CONCLUSIONS' named entity 'CONSECUTIVE' named entity '288' named entity 'IMMUNOCOMPROMISED PATIENTS' named entity 'CLINICAL CHARACTERISTICS' named entity 'TIME' named entity 'CLINICAL' named entity 'SHOCK' named entity 'LOOK' named entity 'IMMUNOSUPPRESSION' named entity 'TRANSPLANT RECIPIENTS' named entity 'ASSESS' named entity 'MULTIPLEX' named entity 'FOUND' named entity '0.09' named entity 'RESPIRATORY VIRUSES' named entity '0.92' named entity 'ASPIRATES' named entity 'MORTALITY' named entity 'TESTING' named entity 'SOLID' named entity 'PERFORMED' named entity 'RESPIRATORY VIRUS' named entity 'TESTED FOR' named entity 'MMA' named entity 'SENSITIVITY' named entity 'PRESENTATIONS' named entity 'FAR' named entity 'CLINICAL RELEVANCE' named entity 'IMMUNOFLUORESCENCE' named entity 'RVS' named entity 'ADDED' named entity 'CENTER' named entity 'TESTS' named entity 'CRITICALLY ILL' named entity 'STEM CELL TRANSPLANT' named entity '0.36' named entity 'RENAL REPLACEMENT THERAPY' named entity 'INVESTIGATIONS' named entity 'PROSPECTIVE' named entity 'USE OF' named entity 'USUAL' named entity 'BRONCHOALVEOLAR LAVAGE FLUID' named entity 'SINGLE' named entity 'USING' named entity 'DAYS' named entity 'DETECTION' named entity 'MEANING' named entity 'ICU'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software